Lymphangioleiomyomatosis: Differential diagnosis and optimal management

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 691-700

  Xu, Kai Feng ^a   Lo, Bee Hong ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Diffuse cystic lung diseases; Lymphangioleiomyomatosis; Sirolimus; Tuberous sclerosis complex; Vascular endothelial growth factor D

Indexed keywords

ATORVASTATIN; DOXYCYCLINE; EVEROLIMUS; HYDROXYCHLOROQUINE; LETROZOLE; PLACEBO; PROGESTERONE; RAPAMYCIN; SIMVASTATIN; TRIPTORELIN; VASCULOTROPIN D;

ACNE; ANGIOMYOLIPOMA; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DYSLIPIDEMIA; GENETIC SCREENING; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LUNG BIOPSY; LUNG CYST; LYMPHANGIOLEIOMYOMATOSIS; MENSTRUAL IRREGULARITY; MOUTH ULCER; PHYSICAL EXAMINATION; PNEUMOTHORAX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUBEROUS SCLEROSIS;

EID: 84928587497     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S50784     Document Type: Review

References (56)

1. McCormack FX, Travis WD, Colby TV, Henske EP, Moss J. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med.2012;186(12): 1210-1212.
2. Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines f or the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J.2010;35(1):14-26.
3. Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the2012 international Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol.2013;49(4):243-254.
4. Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol.2006;4(3):143-152.
5. Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest.2010;138(3):674-681.
6. Xu KF, Zhang P, Tian X, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med.2013;107(2):263-268.
7. Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest.2009;135(5): 1293-1300.
8. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med.2011;364(17): 1595-1606.
9. Young L, Lee HS, Inoue Y, et al. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med.2013;1(6):445-452.
10. Meraj R, Wikenheiser-Brokamp KA, Young LR, Byr nes S, McCormack FX. Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis. Front Med.2012;6(4):395-405.
11. Harari S, Torre O, Cassandro R, Taveira-DaSilva AM, Moss J. Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis. Respir Med.2012;106(9):1286-1292.
12. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A.2004;101(50): 17462-17467.
13. Cai X, Pacheco-Rodriguez G, Fan QY, et al. Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2010;182(11):1410-1418.
14. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol.2005;29(10): 1356-1366.
15. Miyake M, Tateishi U, Maeda T, et al. Pulmonary lymphangioleiomyomatosis in a male patient with tuberous sclerosis complex. Radiat Med.2005;23(7):525-527.
16. Kang HW, Kim CJ, Kang SK, Lee KS, Lee CS, Kim YH. Pulmonary lymphangioleiomyomatosis in a male. J Korean Med Sci. 1991;6(1):83-85.
17. Cudzilo CJ, Szczesniak RD, Brody AS, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest.2013;144(2): 578-585.
18. Hagaman JT, Schauer DP, McCormack FX, Kinder BW. Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective. Am J Respir Crit Care Med.2010;181(12): 1376-1382.
19. Ryu JH, Hartman TE, Torres VE, Decker PA. Frequency of undiagnosed cystic lung disease in patients with sporadic renal angiomyolipomas. Chest.2012;141(1):163-168.
20. Ryu JH, Tian X, Baqir M, Xu K. Diffuse cystic lung diseases. Front Med.2013;7(3):316-327.
21. Trotman-Dickenson B. Cystic lung disease: achieving a radiologic diagnosis. Eur J Radiol.2014;83(1):39-46.
22. Imokawa S, Uehara M, Uto T, et al. Pulmonary metastasis from urothelial carcinoma showing progressive multiple cystic lesions. Am J Respir Crit Care Med.2013;188(10):1267-1268.
23. Baqir M, Kluka EM, Aubry MC, et al. Amyloid-associated cystic lung disease in primary Sjögren's syndrome. Respir Med.2013;107(4):616-621.
24. Lohrmann C, Uhl M, Warnatz K, et al. High-resolution CT imaging of the lung for patients with primary Sjogren's syndrome. Eur J Radiol. 2004;52(2):137-143.
25. Shi JH, Liu HR, Xu WB, et al. Pulmonary manifestations of Sjögren's syndrome. Respiration.2009;78(4):377-386.
26. Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of230 patients at enrollment. Am J Respir Crit Care Med.2006;173(1):105-111.
27. Suri HS, Yi ES, Nowakowski GS, Vassallo R. Pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis.2012;7:16.
28. Furuya M, Nakatani Y. Birt-Hogg-Dube syndrome: clinicopathological features of the lung. J Clin Pathol.2013;66(3):178-186.
29. Koo HK, Yoo CG. Multiple cystic lung disease. Tuberc Respir Dis (Seoul).2013;74(3):97-103.
30. Avila NA, Dwyer AJ, Rabel A, Moss J. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. Radiology. 2007;242(1):277-285.
31. Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med.2001;164(4):661-668.
32. McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest. 2008;133(2):507-516.
33. Gu X, Yu JJ, Ilter D, Blenis N, Henske EP, Blenis J. Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis. Proc Natl Acad Sci U S A.2013;110(37):14960-14965.
34. Yu JJ, Robb VA, Morrison TA, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A.2009;106(8):2635-2640.
35. El-Chemaly S, Henske EP. Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. Eur Respir Rev. 2014;23(131):30-35.
36. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A.2000;97(11): 6085-6090.
37. World Health Organization. World Health Organization Classification of Tumors. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Lyon: IARC Press;2004. Available from: http:// www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/BB10.pdf. Accessed July16,2014.
38. Taveira-DaSilva AM, Hedin C, Stylianou MP, et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med.2001;164(6): 1072-1076.
39. Xu KF, Wang L, Tian XL, et al. The St George's Respiratory Questionnaire in lymphangioleiomyomatosis. Chin Med Sci J. 2010;25(3):140-145.
40. Swigris JJ, Lee HS, Cohen M, et al. St George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis. Chest.2013;143(6):1671-1678.
41. Cottin V, Harari S, Humbert M, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in20 patients. Eur Respir J.2012;40(3):630-640.
42. Taveira-DaSilva AM, Hathaway OM, Sachdev V, Shizukuda Y, Birdsall CW, Moss J. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest. 2007;132(5):1573-1578.
43. Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem.2002;277(34): 30958-30967.
44. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med.2008;358(2):140-151.
45. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med.2011;154(12):797-805.
46. Ando K, Kurihara M, Kataoka H, et al. The efficacy and safety of lowdose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig.2013;51(3):175-183.
47. Braun M, Young J, Reiner CS, et al. Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial. PloS One.2012;7(10):e45868.
48. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet.2013;381(9869):817-824.
49. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase3trial. Lancet.2013;381(9861):125-132.
50. Goldberg HJ, Harari S, McCormack FX, et al. Efficacy and safety of everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. In: The LAM Foundation17th Annual Inter national Lymphangioleiomyomatosis Research Conference and Patient and Family Educational LAMposium; March27-29,2014; Chicago.
51. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med.2006;354(24):2621-2622.
52. Pimenta SP, Baldi BG, Kairalla RA, Carvalho CR. Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response. J Bras Pneumol.2013;39(1):5-15.
53. Chang WY, Cane JL, Kumaran M, Lewis S, Tattersfield AE, Johnson SR. A2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J.2014;43(4): 1114-1123.
54. Harari S, Cassandro R, Chiodini I, Taveira-DaSilva AM, Moss J. Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest.2008;133(2):448-454.
55. El-Chemaly S, Taveira-DaSilva A, Stylianou MP, Moss J. Statins in lymphangioleiomyomatosis: a word of caution. Eur Respir J. 2009;34(2):513-514.
56. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest.2004;126(6):1867-1874.